Skip to main content
Erschienen in: Journal of Gastroenterology 7/2009

01.07.2009 | Original Article—Alimentary Tract

Detection of anti-CUEC-23 antibodies in serum of patients with esophageal squamous cell carcinoma: a possible new serum marker for esophageal cancer

verfasst von: Hideaki Shimada, Akiko Kagaya, Tooru Shiratori, Fumio Nomura, Masaki Takiguchi, Hisahiro Matsubara, Takaki Hiwasa

Erschienen in: Journal of Gastroenterology | Ausgabe 7/2009

Einloggen, um Zugang zu erhalten

Abstract

Background

Serological identification of antigens by recombinant cDNA expression cloning (SEREX) is an established method for detecting new tumor-specific antigens. Antibodies to SEREX antigens may be useful for the detection of esophageal squamous cell carcinoma (SCC).

Methods

A phage cDNA library of a human esophageal SCC cell line was screened using sera of patients with esophageal SCC. The presence and levels of serum antibodies to SEREX antigens were established by Western blotting and enzyme-linked immunosorbent assay (ELISA) using purified recombinant antigen proteins, respectively.

Results

The newly identified esophageal SCC antigen is encoded by a novel gene located on chromosome 1, here designated CUEC-23. Serum CUEC-23-antibodies (s-CUEC-23-Abs) were detected in 14 of 54 patients with esophageal SCC (26%) by Western blot analysis. Esophageal SCCs were positive for s-CUEC-23-Abs together with CEA, SCC-Ag or CYFRA21-1 in 44, 41 and 52% of cases, respectively. There was no detectable association between the presence of s-CUEC-23-Abs and clinicopathological variables. ELISA showed that the levels of s-CUEC-23-Abs were significantly higher in patients with esophageal SCC than in healthy volunteers (17% in the former using the mean + 3 SD of s-CUEC-23-Abs in healthy controls as the cutoff).

Conclusion

A new tumor antigen, CUEC-23, was identified by SEREX screening. s-CUEC-23-Abs might be a useful serum marker to detect esophageal SCC.
Literatur
1.
Zurück zum Zitat Sahin U, Türeci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA. 1995;92:11810–3.PubMedCrossRef Sahin U, Türeci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, et al. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA. 1995;92:11810–3.PubMedCrossRef
2.
Zurück zum Zitat Chen YT, Scanlan MJ, Sahin U, Türeci O, Gure AO, Tsang S, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA. 1997;94:1914–8.PubMedCrossRef Chen YT, Scanlan MJ, Sahin U, Türeci O, Gure AO, Tsang S, et al. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci USA. 1997;94:1914–8.PubMedCrossRef
3.
Zurück zum Zitat Akcakanat A, Kanda T, Koyama Y, Watanabe M, Kimura E, Yoshida Y, et al. NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer. Cancer Chemother Pharmacol. 2004;54:95–100.PubMedCrossRef Akcakanat A, Kanda T, Koyama Y, Watanabe M, Kimura E, Yoshida Y, et al. NY-ESO-1 expression and its serum immunoreactivity in esophageal cancer. Cancer Chemother Pharmacol. 2004;54:95–100.PubMedCrossRef
5.
Zurück zum Zitat Shimada H, Takeda A, Arima M, Okazumi S, Matsubara H, Nabeya Y, et al. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Cancer. 2000;89:1677–83.PubMedCrossRef Shimada H, Takeda A, Arima M, Okazumi S, Matsubara H, Nabeya Y, et al. Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Cancer. 2000;89:1677–83.PubMedCrossRef
6.
Zurück zum Zitat Shimada H, Nabeya Y, Okazumi S, Matsubara H, Funami Y, Shiratori T, et al. Prognostic significance of serum p53 antibody in patients with esophageal squamous cell carcinoma. Surgery. 2002;132:41–7.PubMedCrossRef Shimada H, Nabeya Y, Okazumi S, Matsubara H, Funami Y, Shiratori T, et al. Prognostic significance of serum p53 antibody in patients with esophageal squamous cell carcinoma. Surgery. 2002;132:41–7.PubMedCrossRef
7.
Zurück zum Zitat Takahashi K, Miyashita M, Nomura T, Makino H, Futami R, Kashiwabara M, et al. Serum p53 antibody as a predictor of early recurrence in patients with postoperative esophageal squamous cell carcinoma. Dis Esophagus. 2007;20:117–22.PubMedCrossRef Takahashi K, Miyashita M, Nomura T, Makino H, Futami R, Kashiwabara M, et al. Serum p53 antibody as a predictor of early recurrence in patients with postoperative esophageal squamous cell carcinoma. Dis Esophagus. 2007;20:117–22.PubMedCrossRef
8.
Zurück zum Zitat Nakashima K, Shimada H, Ochiai T, Kuboshima M, Kuroiwa N, Okazumi S, et al. Serological identification of TROP2 by recombinant cDNA expression cloning using sera of patients with esophageal squamous cell carcinoma. Int J Cancer. 2004;112:1029–35.PubMedCrossRef Nakashima K, Shimada H, Ochiai T, Kuboshima M, Kuroiwa N, Okazumi S, et al. Serological identification of TROP2 by recombinant cDNA expression cloning using sera of patients with esophageal squamous cell carcinoma. Int J Cancer. 2004;112:1029–35.PubMedCrossRef
9.
Zurück zum Zitat Shimada H, Nakashima K, Ochiai T, Nabeya Y, Takiguchi M, Nomura F, et al. Serological identification of tumor antigens of esophageal squamous cell carcinoma. Int J Oncol. 2005;26:77–86.PubMed Shimada H, Nakashima K, Ochiai T, Nabeya Y, Takiguchi M, Nomura F, et al. Serological identification of tumor antigens of esophageal squamous cell carcinoma. Int J Oncol. 2005;26:77–86.PubMed
10.
Zurück zum Zitat Kuboshima M, Shimada H, Liu TL, Nakashima K, Nomura F, Takiguchi M, et al. Identification of a novel SEREX antigen, SLC2A1/GLUT1, in esophageal squamous cell carcinoma. Int J Oncol. 2006;28:463–8.PubMed Kuboshima M, Shimada H, Liu TL, Nakashima K, Nomura F, Takiguchi M, et al. Identification of a novel SEREX antigen, SLC2A1/GLUT1, in esophageal squamous cell carcinoma. Int J Oncol. 2006;28:463–8.PubMed
11.
Zurück zum Zitat Kuboshima M, Shimada H, Liu TL, Nomura F, Takiguchi M, Hiwasa T, et al. Presence of serum TRIM21 antibodies in patients with esophageal squamous cell carcinoma. Cancer Sci. 2006;97:380–6.PubMedCrossRef Kuboshima M, Shimada H, Liu TL, Nomura F, Takiguchi M, Hiwasa T, et al. Presence of serum TRIM21 antibodies in patients with esophageal squamous cell carcinoma. Cancer Sci. 2006;97:380–6.PubMedCrossRef
12.
Zurück zum Zitat Hiwasa T, Shimada H, Ochiai T, Takiguchi M. Serological identification of antigens by recombinant cDNA expression cloning (SEREX) using antibodies from patients with esophageal squamous cell carcinoma. In: Hiwasa T, editor. Moleculomics and thereafter. Kerala: Research Signpost; 2006. p. 99–117. Hiwasa T, Shimada H, Ochiai T, Takiguchi M. Serological identification of antigens by recombinant cDNA expression cloning (SEREX) using antibodies from patients with esophageal squamous cell carcinoma. In: Hiwasa T, editor. Moleculomics and thereafter. Kerala: Research Signpost; 2006. p. 99–117.
13.
Zurück zum Zitat Shimada H, Kuboshima M, Shiratori T, Nabeya Y, Takeuchi A, Takagi H, et al. Serum anti-myogegalin antibodies in patients with esophageal squamous cell carcinoma. Int J Oncol. 2007;30:97–103.PubMed Shimada H, Kuboshima M, Shiratori T, Nabeya Y, Takeuchi A, Takagi H, et al. Serum anti-myogegalin antibodies in patients with esophageal squamous cell carcinoma. Int J Oncol. 2007;30:97–103.PubMed
14.
Zurück zum Zitat Takahashi K, Kanazawa H, Chan H, Hosono T, Takahara M, Sato K. A case of esophageal carcinoma metastatic to the mandible and characterization of two cell lines (T.T. and T.Tn.). Jpn J Oral Maxillofac Surg. 1990;36:307–16. Takahashi K, Kanazawa H, Chan H, Hosono T, Takahara M, Sato K. A case of esophageal carcinoma metastatic to the mandible and characterization of two cell lines (T.T. and T.Tn.). Jpn J Oral Maxillofac Surg. 1990;36:307–16.
15.
Zurück zum Zitat Sobin LH, Wittekind CH, editors. UICC TNM classification of malignant tumors. 6th ed. New York: Wiley; 2000. Sobin LH, Wittekind CH, editors. UICC TNM classification of malignant tumors. 6th ed. New York: Wiley; 2000.
16.
Zurück zum Zitat Shimada H, Nabeya Y, Okazumi S, Matsubara H, Miyazawa Y, Shiratori T, et al. Significance of serum CYFRA21–1 in the patients with esophageal squamous cell carcinoma. J Am Coll Surg. 2003;196:573–8.PubMedCrossRef Shimada H, Nabeya Y, Okazumi S, Matsubara H, Miyazawa Y, Shiratori T, et al. Significance of serum CYFRA21–1 in the patients with esophageal squamous cell carcinoma. J Am Coll Surg. 2003;196:573–8.PubMedCrossRef
17.
Zurück zum Zitat Shimada H, Nabeya Y, Okazumi S, Matsubara H, Shiratori T, Gunji Y, et al. Prognostic significance of serum SCC-Ag in the patients with esophageal squamous cell carcinoma. Surgery. 2003;133:486–94.PubMedCrossRef Shimada H, Nabeya Y, Okazumi S, Matsubara H, Shiratori T, Gunji Y, et al. Prognostic significance of serum SCC-Ag in the patients with esophageal squamous cell carcinoma. Surgery. 2003;133:486–94.PubMedCrossRef
Metadaten
Titel
Detection of anti-CUEC-23 antibodies in serum of patients with esophageal squamous cell carcinoma: a possible new serum marker for esophageal cancer
verfasst von
Hideaki Shimada
Akiko Kagaya
Tooru Shiratori
Fumio Nomura
Masaki Takiguchi
Hisahiro Matsubara
Takaki Hiwasa
Publikationsdatum
01.07.2009
Verlag
Springer Japan
Erschienen in
Journal of Gastroenterology / Ausgabe 7/2009
Print ISSN: 0944-1174
Elektronische ISSN: 1435-5922
DOI
https://doi.org/10.1007/s00535-009-0060-8

Weitere Artikel der Ausgabe 7/2009

Journal of Gastroenterology 7/2009 Zur Ausgabe

Original Article—Liver, Pancreas, and Biliary Tract

Diagnostic utility of biopsy specimens for autoimmune pancreatitis

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren. 

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.